Although several FLT3 inhibitors have been discovered and tested in clinical trials, gilteritinib (GLT) is currently the only medication approved by the U.S. Food and Drug Administration (FDA) as a monotherapy for the treatment of AML patients harboring FLT3 mutations [3]. Here, FLT3 is linked to acute myeloid leukemia.